



-1644
RFL

CERTIFICATE OF MAILING

Inventors: Gregory Burrows; Arthur A. Vandenburg

Serial No.: 09/847,172

Patent No.: N/A


Title of Invention: Recombinant MHC Molecules Useful For
Manipulation of Antigen-Specific T-Cells

Atty. Docket. No.: 2357-003-03

CERTIFICATE OF MAILING OR TRANSMISSION

Date of Deposit: May 23, 2005

I hereby certify that this paper or fee is being deposited with the United States Postal Service, first class postage prepaid on the date indicated above and is addressed to The Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 by


Susan M. Wanger

Enclosures:
Transmittal – Supplemental IDS
Supplemental IDS
Return Postcard.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: BURROWS, Gregory G. Burrows; VANDENBARK, Arthur A.

Title: Recombinant MHC Molecules Useful For
Manipulation Of Antigen-Specific T-Cells

Application No.: 09/847,172


Filing Date: May 1, 2001

Examiner/Unit: Amy DeCloux/1644

Attorney Docket No.: 2357-003-03

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposited in the United States Postal Service as First Class mail in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on May 23, 2005.


Susan M. Wanger

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR § 1.97 (As Amended)

TO THE COMMISSIONER FOR PATENTS:

In compliance with Applicants' and their attorney's duty of disclosure under 37 CFR § 1.56, Applicants submit herewith patents, publications, or other information of which they are aware and which they believe may be material to the examination of this application. This Supplemental Information Disclosure is being filed within ninety (90) days of receipt of the material cited on the attached PTO Form 1449. No filing fees are required to file the Supplemental Information Disclosure Statement. However, if the

Patent Office determines that a fee is required for Applicants to file this Information Disclosure Statement, please charge any fees, or credit overpayment to Deposit Account No. 07-1897.


While this Supplemental Information Disclosure Statement may disclose "material" information pursuant to 37 CFR § 1.56, it is not intended to constitute an admission that any patent, publication, or other information referred to therein is "prior art" for this invention unless specifically designated as such. In accordance with 37 CFR § 1.97(g) and (h), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR § 1.56(b) exists.

Applicant further declares in accordance with 37 CFR § 197(e)(2) that no item of information contained in the supplemental information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the supplemental information disclosure statement was known to any individual designated in Sec. 1.56(c) more than three months prior to the filing of the supplemental information disclosure statement.

Copies of the documents cited in the attached form are enclosed.

Respectfully submitted,

GRAYBEAL JACKSON HALEY LLP



Jeffrey J. King
Attorney for Applicant
Registration No. 38,515
155-108th Avenue N.E., Suite. 350
Bellevue, Washington 98004-5901
Telephone: (425) 455-5575
Facsimile: (425) 455-1046

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS


Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (If known)				
	1	PCT/US98/18244 (WO 99/14236)	03/25/1999	Gregory G. Burrows, et al		
	2	PCT/US95/02689 (WO 95/23814)	09/08/1995	National Jewish Center For Immunology and Respiratory Medicine		
	3	PCT/US97/20023 (WO 99/09064)	02/25/2999	CASARES, Sofia; BRUMEANU, Tedor, Doru; BONA, Constantin		
	4.	EP No. 02766900.1 (Search Report)	02/23/05	Gregory G. Burrows, et al		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08b(08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 14496 PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2

of 2

Complete if Known

Application Number	09/847,172
Filing Date	May 1, 2001
First Named Inventor	Burrows
Art Unit	1644
Examiner Name	Amy DeCloux
Attorney Docket Number	2357-003-03

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	BURROWS, G., et al "Two-Domain MHC Class II Molecules Form Stable Complexes With Myelin Basic Protein 69-89 Peptide That Detect And Inhibit Rat Encephalitogenic T-Cells And Treat Experimental Autoimmune Encephalomyelitis" JOURNAL OF IMMUNOLOGY (Baltimore, MD - US) Vol. 161, 1998; PP. 5987-5996	
	2	BURROWS, G., et al "Regulation of Encephalitogenic T Cells With Recombinant TCR Ligands:" JOURNAL OF IMMUNOLOGY (Baltimore, MD - US) Vol. 164, No. 12, June 15, 2000 (2000-06-15) PP. 6636-6371	
	3	SMITH, K. J., et al "Crystal Structure of HLA-DR2 (DRA*0101, DRB1*1501) Complexed With A Peptide From Human Myelin Basic Protein" JOURNAL OF EXPERIMENTAL MEDICINE (Tokyo, JP) Vol. 18, No. 8, October 19, 1998 (1998-10-19) PP. 1511-1520	
	4.	LI, Y., et al "Structural Basis For The Binding Of An Immunodominant Peptide From Myelin Basic Protein In Different Registers By Two HLA-DR2 Proteins" JOURNAL OF MOLECULAR BIOLOGY (London, GB) Vol. 304, No. 2, November 24, 2000 (2000-11-24); PP. 177-188	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.